Trial Profile
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Beloranib (Primary)
- Indications Hypothalamic disorders; Obesity
- Focus Proof of concept; Therapeutic Use
- Sponsors Zafgen
- 08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.
- 07 Mar 2015 According to a Zafgen media release, results were presented at the Endocrine Society Annual Meeting (ENDO) 2015.
- 07 Mar 2015 Results published in a Zafgen media release.